This session at ESC 2025 highlighted advances in hypertension treatment exhibiting quadpill efficacy, stroke risk reduction, dapagliflozin benefits, telemonitoring, spironolactone’s mortality impact, & effect of RAAS drug on brain health.

The session highlights the latest research on efficacy and safety of glucagon like peptide-1agonists and sodium-glucose cotransporter-2 inhibitors in various disease including atrial fibrillation and high-risk diabetes.

Research involving 860,042 births found that preexisting maternal diabetes more than doubled stillbirth risk (RR 2.68), with the highest risk seen in macrosomic infants >97th birth weight centile (type 1: RR 3.96; type 2: RR 4.02). GDM vs no diabetes was tied to lower risk of still births (diet-controlled: RR:0.75; insulin-controlled: RR:0.37). Diabetic women delivered earlier & had more iatrogenic births.

Women with multiple chronic conditions (MCC) before pregnancy faced sharply higher severe maternal morbidity or mortality (SMM-M) risk within 42 days postpartum (aRR 1.38 for 1 condition, aRR 1.82 for 2, aRR 2.75 for ≥3). Complex MCC (≥3 conditions in ≥3 body systems) and ≥3 cardiometabolic conditions further elevated the risk (aRR 2.92 & aRR 5.45, resp.). Emergency visits and hospitalization also increased with MCC.